Biomarkers Market Exceeds 25 Billion: Kalorama Report

The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline, according to the latest Kalorama Information report, “The Global Market for Biomarkers.”

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report.

New York, NY (PRWEB) October 30, 2013

The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year, according to an estimate from Kalorama Information. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline, according to Kalorama Information’s new report on the industry, “The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers)."

Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging. Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body’s tissues, and can suggest a cardiovascular event when levels are high.

“Biomarkers like CK-MB have many positive benefits to medicine,” said Melissa Elder, Kalorama analyst and author of the report. “Diseases are detected earlier, more effective treatments can be delivered, drug reactions reduced.”

The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report.

The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx.

Kalorama Information’s report, “The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers)” contains detailed breakouts of biomarker market segments, disease statistics and company profiles. More information about the report can be obtained at Kalorama Information’s website: http://www.kaloramainformation.com/Global-Biomarkers-Cancer-7836984/

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn